United Laboratories’ UBT251 Shows Promising Trial Results

The United Laboratories International Holdings (HK:3933) has released an update.

The United Laboratories International Holdings Limited has announced the successful completion of Phase Ia clinical trials for their new drug, UBT251 Injection, in China. The drug, a first-in-class long-acting triple agonist, demonstrated safety, tolerability, and linear pharmacokinetics when administered to healthy subjects. Furthermore, it showed promising results in reducing body weight compared to a placebo, positioning the company as a pioneer in the Chinese biopharmaceutical industry.

For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.